Safety and outcome of treatment of metastatic melanoma using 3-bromopyruvate: A concise literature review and case study

Chinese Journal of Cancer

Volumn 33, Issue 7, 2014, Pages 356-364

  El Sayed, Salah Mohamed ^a   Mohamed, Walaa Gamal ^a   Hassan Seddik, Minnat Allah ^a   Ahmed Ahmed, Al Shimaa ^a   Mahmoud, Asmaa Gamal ^a   Amer, Wael Hassan ^b   Helmy Nabo, Manal Mohamed ^c,d   Hamed, Ahmed Roshdi ^e   Ahmed, Nagwa Sayed ^a   Abd Allah, Ali Abdel Rahman ^a  

^a SOHAG UNIVERSITY   (Egypt)

^b Sohage University   (Egypt)

^c Sohag University   (Egypt)

^d Department of Pediatrics Sohag Teaching Hospital ^*  (Saudi Arabia)

^e Sohag University   (Egypt)

Author keywords

3 bromopyruvate; Lactate dehydrogenase; Melanoma; Paracetamol; Warburg effect

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BROMOPYRUVIC ACID; DICLOFENAC; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; FENTANYL; GLUTATHIONE; HUMAN ALBUMIN; HYDROXYPROGESTERONE CAPROATE; IBUPROFEN; LACTATE DEHYDROGENASE; PARACETAMOL; PYRUVIC ACID DERIVATIVE; UNCLASSIFIED DRUG; BROMOPYRUVATE; ENZYME INHIBITOR; HEXOKINASE; LACTIC ACID;

ADULT; ANASARCA; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATELECTASIS; BACKACHE; BACTERIAL PNEUMONIA; BURNING SENSATION; CASE REPORT; CELL DEATH; CHEST INFECTION; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CYTOTOXICITY; DEXTROCARDIA; DYSPNEA; ECHOCARDIOGRAPHY; ELEVATED BLOOD PRESSURE; FEVER; HEART TAMPONADE; HUMAN; HUMAN TISSUE; HYPOALBUMINEMIA; HYPOPROTEINEMIA; HYPOTENSION; HYPOXEMIA; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTOSIS; LUNG INJURY; MALE; METASTATIC MELANOMA; NEUTROPHILIA; NUTRITIONAL DEFICIENCY; OXIDATIVE STRESS; OXYGEN MASK; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PLEURA EFFUSION; RADIODIAGNOSIS; RESPIRATORY DISTRESS; THORAX PAIN; THORAX RADIOGRAPHY; TREATMENT OUTCOME; UREA BLOOD LEVEL; DISEASE COURSE; DRUG COMBINATION; GLYCOLYSIS; LIVER CELL CARCINOMA; LUNG TUMOR; MELANOMA; NECROSIS; NEOVASCULARIZATION (PATHOLOGY); PLEURA TUMOR; PROGNOSIS; SECONDARY;

ACETAMINOPHEN; ADULT; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; GLUTATHIONE; GLYCOLYSIS; HEXOKINASE; HUMANS; L-LACTATE DEHYDROGENASE; LACTIC ACID; LUNG NEOPLASMS; MALE; MELANOMA; NECROSIS; NEOVASCULARIZATION, PATHOLOGIC; PLEURAL NEOPLASMS; PROGNOSIS; PYRUVATES; TREATMENT OUTCOME;

EID: 84903905450     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.013.10111     Document Type: Article

References (39)

1. Nakajima EC, Van Houten B. Metabolic symbiosis in cancer: refocusing the Warburg lens. Mol Carcinog, 2012, 52: 329-337.
2. Ho J, de Moura MB, Lin Y, et al. Importance of glycolysis and oxidative phosphorylation in advanced melanoma. Mol Cancer, 2012, 11: 76-88.
3. Warburg O. On the origin of cancer cells. Science, 1956, 123: 309-314.
4. Scott DA, Richardson AD, Filipp FV, et al. Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect. J Biol Chem, 2011, 286: 42626-42634.
5. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer, 2004, 4: 891-899.
6. Shime H, Yabu M, Akazawa T, et al. Tumor-secreted lactic acid promotes IL-23/IL-17 proinflammatory pathway. J Immunol, 2008, 180: 7175-7183.
7. Végran F, Boidot R, Michiels C, et al. Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-κB/IL-8 pathway that drives tumor angiogenesis. Cancer Res, 2011, 71: 2550-2560.
8. Hirschhaeuser F, Sattler UG, Mueller-Klieser W. Lactate: a metabolic key player in cancer. Cancer Res, 2011, 71: 6921-6925.
9. Walenta S, Mueller-Klieser WF, Lactate: mirror and motor of tumor malignancy. Semin Radiat Oncol, 2004, 14: 267-274.
10. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol, 2009, 27: 6199-6206.
11. Agarwala SS, Keilholz U, Gilles E, et al. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J Cancer, 2009, 45: 1807-1814.
12. Qin JZ, Xin H, Nickoloff BJ. 3-Bromopyruvate induces necrotic cell death in sensitive melanoma cell lines. Biochem Biophys Res Commun, 2010, 396: 495-500.
13. Hulleman E, Kazemier, KM, Holleman A, et al. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood, 2009, 113: 2014-2021.
14. Matsushita K, Uchida K, Saigusa S, et al. Glycolysis inhibitors as a potential therapeutic option to treat aggressive neuroblastoma expressing GLUT1. J Pediatr Surg, 2012, 47: 1323-1330.
15. El Sayed SM, Abou El-Magd RM, Shishido Y, et al. D-amino acid oxidase gene therapy sensitizes glioma cells to the antiglycolytic effect of 3-brmopyruvate. Cancer Gene Ther, 2012, 19: 1-18.
16. Ko YH, Verhoeven HA, Lee MJ, et al. A translational study "case report" on the small molecule "energy blocker" 3-bromopyruvate (3BP) as a potent anticancer agent: from bench side to bedside. J Bioenerg Biomembr, 2012, 44: 163-170.
17. Ko YH, Smith BL, Wang Y, et al. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun, 2004, 324: 269-275.
18. Buijs M, Vossen JA, Geschwind JF, et al. Specificity of the antiglycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer. Invest New Drugs, 2009, 27: 120-123.
19. Nakano A, Tsuji D, Miki H, et al. Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells. PLoS One, 2011, 6: 1-10.
20. El Sayed SM, El-Magd RM, Shishido Y, et al. D-Amino acid oxidase-induced oxidative stress, 3-bromopyruvate and citrate inhibit angiogenesis, exhibiting potent anticancer effects. J Bioenerg Biomembr, 2012, 44: 513-523.
21. Barnard JP, Reynafarje B, Pedersen PL. Glucose catabolism in African trypanosomes. Evidence that the terminal step is catalyzed by a pyruvate transporter capable of facilitating uptake of toxic analogs. J Biol Chem, 1993, 268: 3654-3661.
22. Mulet C, Lederer F. Bromopyruvate as an affinity label for baker's yeast flavocytochrome b2. Kinetic study of the inactivation reaction. Eur J Biochem, 1977, 73: 443-447.
23. El Sayed SM, El-Magd RM, Shishido Y, et al. 3-Bromopyruvate antagonizes effects of lactate and pyruvate, synergizes with citrate and exerts novel anti-glioma effects. J Bioenerg Biomembr, 2012, 44: 61-79.
24. Vali M, Liapi E, Kowalski J, et al. Intraarterial therapy with a new potent inhibitor of tumor metabolism (3-bromopyruvate): identification of therapeutic dose and method of injection in an animal model of liver cancer. J Vasc Interv Radiol, 2007, 18: 95-101.
25. Geschwind JF, Ko YH, Torbenson MS, et al. Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res, 2002, 62: 3909-3913.
26. Magrath IT. The treatment of pediatric lymphomas: paradigms to plagiarize? Ann Oncol, 1997, 1: 7-14.
27. McCullough HN. Acetaminophen and ibuprofen in the management of fever and mild to moderate pain in children. Paediatr Child Health, 1998, 3: 246-250.
28. Gregoire N, Hovsepian L, Gualano V, et al. Safety and pharmacokinetics of paracetamol following intravenous administration of 5 g during the first 24 h with a 2-g starting dose. Clin Pharmacol Ther, 2007, 81: 401-405.
29. Kuffner EK, Dart RC. Acetaminophen use in patients who drink alcohol: current study evidence. Am J Manag Care, 2001, 7: 592-596.
30. Vad NM, Yount G, Moore D, et al. Biochemical mechanism of acetaminophen (APAP) induced toxicity in melanoma cell lines. J Pharm Sci, 2009, 98: 1409-1425.
31. Vad NM, Kudugunti SK, Graber D, et al. Efficacy of acetaminophen in skin B16-F0 melanoma tumor-bearing C57BL/6 mice. Int J Oncol, 2009, 35: 193-204.
32. Wolchok JD, Williams L, Pinto JT, et al. Phase I trial of high dose paracetamol and carmustine inpatients with metastatic melanoma. Melanoma Res, 2003, 13: 189-196.
33. Al-Saadoon EA, Al-Naama LM, Hassan JK. Serum lactate dehydrogenase (LDH) activity in children with malignant diseases. Bahrain Med Bull, 2003, 25: 1-5.
34. Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis, 2013, 4: 1-10.
35. Bánfalvi T, Edesné MB, Gergye M, et al. Laboratory markers of melanoma progression. Magy Onkol, 2003, 47: 89-104.
36. Dell'Antone P. Targets of 3-bromopyruvate, a new, energy depleting, anticancer agent. Med Chem, 2009, 5: 491-416.
37. Fang J, Quinones QJ, Holman TL, et al. The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. Mol Pharmacol, 2006, 70: 2108-2115.
38. Olaleye MT, Akinmoladun AC, Ogunboye AA, et al. Antioxidant activity and hepatoprotective property of leaf extracts of Boerhaavia diffusa Linn against acetaminophen-induced liver damage in rats. Food Chem Toxicol, 2010, 48: 2200-2205.
39. El Sayed SM, Mahmoud AA, El Sawy SA, et al. Warburg effect increases steady-state ROS condition in cancer cells through decreasing their antioxidant capacities (anticancer effects of 3-bromopyruvate through antagonizing Warburg effect). Med Hypotheses, 2013, 81: 866-870.